Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Lung Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is a open-label, multi-center, prospective, single-arm clinical trialMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
This is a prospective, open-label, multi-center, single-arm clinical trial aimed at patients with advanced non-small cell lung cancer (NSCLC) with asymptomatic brain metastases with epidermal growth factor receptor sensitive mutations (EGFRm+) who have not received any systemic treatment To evaluate...
This is a prospective, open-label, multi-center, single-arm clinical trial aimed at patients with advanced non-small cell lung cancer (NSCLC) with asymptomatic brain metastases with epidermal growth factor receptor sensitive mutations (EGFRm+) who have not received any systemic treatment To evaluate the effectiveness and safety of high-dose almonertinib mesylate.Eligible patients were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.
Tracking Information
- NCT #
- NCT04808752
- Collaborators
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Investigators
- Principal Investigator: Qin Li Lu Zhejiang Provincial People's Hospital?Hangzhou, China Principal Investigator: Jun Chen Ningbo Yinzhou People's Hospital?Ningbo, China Principal Investigator: Ping Yu Li The First Affiliated Hospital of Wenzhou Medical University?Wenzhou?China Principal Investigator: Fei J Zhu Taizhou Central Hospital?Taizhou?China Principal Investigator: Bin Wang Huzhou Central Hospital?Taizhou?China Principal Investigator: Wu G Wu Meizhou People's Hospital?Meizhou?China Principal Investigator: Rong R Zhou Xiangya Hospital of Central South University?Changsha?China Principal Investigator: Yan X Lin Union Hospital Affiliated to Fujian Medical University?Fujian?China Principal Investigator: Yan Yu Heilongjiang Cancer Hospital?Heilongjiang?China Principal Investigator: Jun G Zhang The First Affiliated Hospital of Zhengzhou University?Zhengzhou,China Principal Investigator: Qiu Y Zhao Henan Cancer Hospital?Henan?China
Get Well Soon